EUVIMEDEUVIMED entdecken
Crossref

MYBL2 promotes proliferation of clear cell renal cell carcinoma by regulating TOP2A and activating AKT / mTOR signaling pathway

Yawei Huang iD, Xiaoqing Xi iD, Zhenfeng Ye iD, Chiyu Zhang iD, Yi Jiang iD, Fanfan Yu iD, Gaomin Huang iD

The FASEB Journal · 31.01.2025 · 39 (2)

DOI: 10.1096/fj.202401910r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 20.01.2025. Verfasst von Yawei Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Second Affiliated Hospital of Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, TOR Serine-Threonine Kinases, Kidney Neoplasms, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Nature Science Foundation of China, Incubation Program of Second Affiliated Hospital of Nanchang University, Science and Technology Program of the Jiangxi Provincial Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal cell carcinoma (RCC) is one of the most common malignancies in the urinary system, and clear cell renal cell carcinoma (ccRCC) is the most common subtype. MYBL2 has been reported to be overexpressed in various tumors and associated with poor prognosis in patients, but its biological role in ccRCC remains unclear. In this study, we investigated the mRNA and protein expression levels of MYBL2 in ccRCC samples and evaluated the prognostic value of MYBL2 using TCGA dataset. In vitro functional assays were performed using CCK‐8, EdU, colony formation, cell scratch, and transwell assays, as well as in vivo tumorigenesis assays to investigate the biological functions of MYBL2 in ccRCC. Additionally, gene set enrichment analysis (GSEA) was used to explore the downstream pathways of MYBL2, which were further validated. Finally, we predicted the target genes of MYBL2 using bioinformatics and validated them using ChIP and dual‐luciferase reporter gene assays. MYBL2 expression was significantly higher in ccRCC than in adjacent normal tissues and was associated with poor prognosis. MYBL2 expression was positively correlated with the pathological tumor grade and clinical TNM stage of ccRCC patients. Knockdown of MYBL2 significantly inhibited the proliferation of renal cancer cells in vitro and in vivo, and knockdown of MYBL2 could inhibit cell invasion and migration, while overexpression of MYBL2 had the opposite effect. GSEA revealed that MYBL2 was associated with the mTOR signaling pathway and cell cycle pathway, which was confirmed by our study. Finally, we found that TOP2A was a target gene of MYBL2, and MYBL2 could bind to the TOP2A promoter to regulate its transcriptional activity, promoting the proliferation of clear cell renal cell carcinoma cells. MYBL2 emerges as a highly expressed factor that significantly correlates with adverse patient prognosis in ccRCC. Mechanistically, MYBL2 transcriptionally upregulates TOP2A, thereby modulating the proliferation of ccRCC cells. Furthermore, MYBL2 activates the mTOR signaling pathway, a critical node in the progression of ccRCC. Collectively, these findings position MYBL2 as a promising candidate for both a biological marker and a therapeutic target in the management of ccRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellTOR Serine-Threonine KinasesKidney NeoplasmsProto-Oncogene Proteins c-aktDNA Topoisomerases, Type IICell Cycle ProteinsPoly-ADP-Ribose Binding ProteinsHumansCell ProliferationSignal TransductionAnimalsMiceFemaleGene Expression Regulation, NeoplasticMaleCell Line, TumorCell MovementPrognosisMice, NudeMiddle AgedMice, Inbred BALB CTrans-Activators

Stichwörter der Autor:innen

MYBL2TOP2AccRCCcell proliferationmTOR

Substanzen

TOR Serine-Threonine KinasesMTOR protein, humanProto-Oncogene Proteins c-aktTOP2A protein, humanDNA Topoisomerases, Type IIMYBL2 protein, humanCell Cycle ProteinsPoly-ADP-Ribose Binding ProteinsTrans-Activators

Autor:innen und Institutionen

  • Department of Urology, Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • Department of Obstetrics and Gynecology, First Affiliated Hospital of Nanchang University, Nanchang, China.

ORCID-Profile: Yawei Huang, Xiaoqing Xi, Zhenfeng Ye, Chiyu Zhang, Yi Jiang, Fanfan Yu, Gaomin Huang

Förderung

  • National Nature Science Foundation of China
  • Incubation Program of Second Affiliated Hospital of Nanchang University
  • Science and Technology Program of the Jiangxi Provincial Health Commission
  • National Natural Science Foundation of China

Zitieren

APA

Huang, Y., Xi, X., Ye, Z., Zhang, C., Jiang, Y., Yu, F., & Huang, G. (2025). MYBL2 promotes proliferation of clear cell renal cell carcinoma by regulating TOP2A and activating AKT / mTOR signaling pathway. The FASEB Journal, 39(2). https://doi.org/10.1096/fj.202401910r

Vancouver

Huang Y, Xi X, Ye Z, Zhang C, Jiang Y, Yu F, et al. MYBL2 promotes proliferation of clear cell renal cell carcinoma by regulating TOP2A and activating AKT / mTOR signaling pathway. The FASEB Journal. 2025;39(2). doi:10.1096/fj.202401910r

BibTeX
@article{Huang2025,
  author = {Huang, Yawei and Xi, Xiaoqing and Ye, Zhenfeng and Zhang, Chiyu and Jiang, Yi and Yu, Fanfan and Huang, Gaomin},
  title = {MYBL2 promotes proliferation of clear cell renal cell carcinoma by regulating TOP2A and activating AKT / mTOR signaling pathway},
  journal = {The FASEB Journal},
  year = {2025},
  volume = {39},
  number = {2},
  doi = {10.1096/fj.202401910r}
}
Kostenlos starten →